What is ViOptix?
ViOptix is a recognized leader in the field of real-time tissue oximetry, dedicated to enhancing surgical procedures by accurately measuring tissue oxygen saturation. Their innovative product line, including T.Ox, T.Ox Remote, and Intra.Ox, is engineered for clinical environments, with a particular focus on applications within breast reconstruction surgery. By providing healthcare professionals and institutions with sophisticated tools, ViOptix aims to bolster clinical confidence and elevate the standard of patient care. The company's commitment to progress is evident in its pursuit of technological advancements and the accumulation of substantial clinical evidence, positioning it as a key player in the medical technology sector.
How much funding has ViOptix raised?
ViOptix has raised a total of $24.4M across 3 funding rounds:
Series C
$9.2M
Series D
$12.2M
Series E
$3M
Series C (2004): $9.2M with participation from IN-vivo Ventures, Morningside Group, MDS Capital, and Trident Investments
Series D (2008): $12.2M led by Morningside Venture Investments
Series E (2010): $3M, investors not publicly disclosed
Key Investors in ViOptix
IN-vivo Ventures
IN-vivo Ventures is an investment firm that likely focuses on companies within the life sciences and medical technology sectors, given its name and participation in ViOptix's funding round.
Morningside Group
Morningside Group is a diversified investment firm with a history of backing companies across various sectors, including real estate and potentially healthcare, as indicated by their involvement with ViOptix.
MDS Capital
MDS Capital Corp is a venture capital firm based in Vancouver, Canada, known for investing in companies within the technology and healthcare industries, aligning with ViOptix's focus.
What's next for ViOptix?
With the recent injection of $3M in a major strategic investment, ViOptix is poised for accelerated growth and enhanced market penetration. This significant capital infusion, part of its overall $24.4M in funding, suggests a transition into a scaling phase, likely focusing on expanding its commercial reach, further developing its product pipeline, and potentially exploring new clinical applications. The strategic nature of this investment indicates a strong belief from backers in ViOptix's technology and its potential to disrupt surgical practices, paving the way for broader adoption and impact on patient care.
See full ViOptix company page
